The Endocannabinoid System: Pivotal Orchestrator of Obesity and Metabolic Disease

Trends in Endocrinology and Metabolism

Volumn 26, Issue 10, 2015, Pages 524-537

  Mazier, Wilfrid ^a,b   Saucisse, Nicolas ^a,b   Gatta Cherifi, Blandine ^a,b,c   Cota, Daniela ^a,b  

^a INSTITUT FRANÇOIS MAGENDIE   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

CB1; Endocannabinoids; Energy balance; Food intake; Metabolism; Obesity

Indexed keywords

AM 4113; AM 6527; AM 6545; CANNABINOID 1 RECEPTOR ANTAGONIST; ENDOCANNABINOID; JD 5037; O 7460; OMEGA 3 FATTY ACID; PREGNENOLONE; RIMONABANT; UNCLASSIFIED DRUG;

BODY MASS; CARDIOMETABOLIC RISK; DIET INDUCED OBESITY; DOPAMINERGIC NERVE CELL; ENERGY BALANCE; ENERGY EXPENDITURE; FAT INTAKE; FAT MASS; FOOD INTAKE; GABAERGIC TRANSMISSION; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIPID COMPOSITION; METABOLIC DISORDER; NEUROTRANSMISSION; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; SMELLING; TASTE; THERMOGENESIS; WAIST CIRCUMFERENCE; ANIMAL; EATING; METABOLISM; PHYSIOLOGY;

ANIMALS; EATING; ENDOCANNABINOIDS; HUMANS; METABOLIC DISEASES; OBESITY;

EID: 84942096043     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2015.07.007     Document Type: Review

References (131)

1. Elphick M.R. The evolution and comparative neurobiology of endocannabinoid signalling. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 2012, 367:3201-3215.
2. Matias I., et al. Endogenous cannabinoids in the brain and peripheral tissues: regulation of their levels and control of food intake. Int. J. Obes. (Lond.) 2006, 30(Suppl. 1):S7-S12.
3. DiPatrizio N.V., Piomelli D. The thrifty lipids: endocannabinoids and the neural control of energy conservation. Trends Neurosci. 2012, 35:403-411.
4. Bermudez-Silva F.J., et al. The role of the endocannabinoid system in the neuroendocrine regulation of energy balance. J. Psychopharmacol. 2012, 26:114-124.
5. Silvestri C., Di Marzo V. The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metab. 2013, 17:475-490.
6. Abel E.L. Cannabis: effects on hunger and thirst. Behav. Biol. 1975, 15:255-281.
7. Muccioli G.G. Endocannabinoid biosynthesis and inactivation, from simple to complex. Drug Discov. Today 2010, 15:474-483.
8. Di Marzo V. Endocannabinoid signaling in the brain: biosynthetic mechanisms in the limelight. Nat. Neurosci. 2011, 14:9-15.
9. Herman C.P., Polivy J. External cues in the control of food intake in humans: the sensory-normative distinction. Physiol. Behav. 2008, 94:722-728.
10. Karine B., et al. Rat strains with different metabolic statuses differ in food olfactory-driven behavior. Behav. Brain Res. 2014, 270:228-239.
11. Thiebaud N., et al. Hyperlipidemic diet causes loss of olfactory sensory neurons, reduces olfactory discrimination, and disrupts odor-reversal learning. J. Neurosci. 2014, 34:6970-6984.
12. Breunig E., et al. The endocannabinoid 2-arachidonoyl-glycerol controls odor sensitivity in larvae of Xenopus laevis. J. Neurosci. 2010, 30:8965-8973.
13. Soria-Gomez E., et al. The endocannabinoid system controls food intake via olfactory processes. Nat. Neurosci. 2014, 17:407-415.
14. Grill H.J., Hayes M.R. Hindbrain neurons as an essential hub in the neuroanatomically distributed control of energy balance. Cell Metab. 2012, 16:296-309.
15. Yoshida R., et al. Endocannabinoids selectively enhance sweet taste. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:935-939.
16. Niki M., et al. Modulation of sweet taste sensitivities by endogenous leptin and endocannabinoids in mice. J. Physiol. 2015, 593:2527-2545.
17. Matias I., et al. Endocannabinoids measurement in human saliva as potential biomarker of obesity. PLoS ONE 2012, 7:e42399.
18. Artmann A., et al. Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochim. Biophys. Acta 2008, 1781:200-212.
19. DiPatrizio N.V., et al. Endocannabinoid signal in the gut controls dietary fat intake. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:12904-12908.
20. DiPatrizio N.V., et al. Endocannabinoid signaling in the gut mediates preference for dietary unsaturated fats. FASEB J. 2013, 27:2513-2520.
21. Gomez R., et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J. Neurosci. 2002, 22:9612-9617.
22. Smeets P.A., et al. Cephalic phase responses and appetite. Nutr. Rev. 2010, 68:643-655.
23. DiPatrizio N.V. Is fat taste ready for primetime?. Physiol. Behav. 2014, 136:145-154.
24. Burdyga G., et al. Expression of cannabinoid CB1 receptors by vagal afferent neurons: kinetics and role in influencing neurochemical phenotype. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 299:G63-G69.
25. Ishac E.J., et al. Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br. J. Pharmacol. 1996, 118:2023-2028.
26. Zbucki R.L., et al. Cannabinoids enhance gastric X/A-like cells activity. Folia Histochem. Cytobiol. 2008, 46:219-224.
27. Senin L.L., et al. The gastric CB1 receptor modulates ghrelin production through the mTOR pathway to regulate food intake. PLoS ONE 2013, 8:e80339.
28. Cai H., et al. Altered lipid and salt taste responsivity in ghrelin and GOAT null mice. PLoS ONE 2013, 8:e76553.
29. Perello M., et al. Ghrelin increases the rewarding value of high-fat diet in an orexin-dependent manner. Biol. Psychiatry 2010, 67:880-886.
30. Ohno-Shosaku T., Kano M. Endocannabinoid-mediated retrograde modulation of synaptic transmission. Curr. Opin. Neurobiol. 2014, 29:1-8.
31. Castillo P.E., et al. Endocannabinoid signaling and synaptic function. Neuron 2012, 76:70-81.
32. Bellocchio L., et al. Bimodal control of stimulated food intake by the endocannabinoid system. Nat. Neurosci. 2010, 13:281-283.
33. Kirkham T.C., et al. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br. J. Pharmacol. 2002, 136:550-557.
34. Mahler S.V., et al. Endocannabinoid hedonic hotspot for sensory pleasure: anandamide in nucleus accumbens shell enhances 'liking' of a sweet reward. Neuropsychopharmacology 2007, 32:2267-2278.
35. Maldonado R., et al. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci. 2006, 29:225-232.
36. Labouebe G., et al. Insulin induces long-term depression of ventral tegmental area dopamine neurons via endocannabinoids. Nat. Neurosci. 2013, 16:300-308.
37. Williams K.W., Elmquist J.K. From neuroanatomy to behavior: central integration of peripheral signals regulating feeding behavior. Nat. Neurosci. 2012, 15:1350-1355.
38. Zeltser L.M., et al. Synaptic plasticity in neuronal circuits regulating energy balance. Nat. Neurosci. 2012, 15:1336-1342.
39. Koch M., et al. Hypothalamic POMC neurons promote cannabinoid-induced feeding. Nature 2015, 519:45-50.
40. Koch M., Horvath T.L. Molecular and cellular regulation of hypothalamic melanocortin neurons controlling food intake and energy metabolism. Mol. Psychiatry 2014, 19:752-761.
41. Benard G., et al. Mitochondrial CB(1) receptors regulate neuronal energy metabolism. Nat. Neurosci. 2012, 15:558-564.
42. Palomba L., et al. Negative regulation of leptin-induced reactive oxygen species (ROS) formation by cannabinoid CB1 receptor activation in hypothalamic neurons. J. Biol. Chem. 2015, 290:13669-13677.
43. Chen Y., et al. Sensory detection of food rapidly modulates arcuate feeding circuits. Cell 2015, 160:829-841.
44. Di Marzo V., et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001, 410:822-825.
45. Jo Y.H., et al. Integration of endocannabinoid and leptin signaling in an appetite-related neural circuit. Neuron 2005, 48:1055-1066.
46. Malcher-Lopes R., et al. Opposing crosstalk between leptin and glucocorticoids rapidly modulates synaptic excitation via endocannabinoid release. J. Neurosci. 2006, 26:6643-6650.
47. Cristino L., et al. Obesity-driven synaptic remodeling affects endocannabinoid control of orexinergic neurons. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:E2229-E2238.
48. Coutts A.A., Pertwee R.G. Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus. Br. J. Pharmacol. 1997, 121:1557-1566.
49. Vianna C.R., et al. Cannabinoid receptor 1 in the vagus nerve is dispensable for body weight homeostasis but required for normal gastrointestinal motility. J. Neurosci. 2012, 32:10331-10337.
50. Bellocchio L., et al. Activation of the sympathetic nervous system mediates hypophagic and anxiety-like effects of CB(1) receptor blockade. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:4786-4791.
51. Quarta C., et al. CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance. Cell Metab. 2010, 11:273-285.
52. Bajzer M., et al. Cannabinoid receptor 1 (CB1) antagonism enhances glucose utilisation and activates brown adipose tissue in diet-induced obese mice. Diabetologia 2011, 54:3121-3131.
53. Cardinal P., et al. Hypothalamic CB1 cannabinoid receptors regulate energy balance in mice. Endocrinology 2012, 153:4136-4143.
54. Cardinal P., et al. CB1 cannabinoid receptor in SF1-expressing neurons of the ventromedial hypothalamus determines metabolic responses to diet and leptin. Mol. Metab. 2014, 3:705-716.
55. Jung K.M., et al. 2-Arachidonoylglycerol signaling in forebrain regulates systemic energy metabolism. Cell Metab. 2012, 15:299-310.
56. Xu Y., et al. Glutamate mediates the function of melanocortin receptor 4 on Sim1 neurons in body weight regulation. Cell Metab. 2013, 18:860-870.
57. Cardinal P., et al. Cannabinoid type 1 (CB1) receptors on Sim1-expressing neurons regulate energy expenditure in male mice. Endocrinology 2015, 156:411-418.
58. Ruby M.A., et al. Overactive endocannabinoid signaling impairs apolipoprotein E-mediated clearance of triglyceride-rich lipoproteins. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:14561-14566.
59. Tedesco L., et al. Cannabinoid receptor stimulation impairs mitochondrial biogenesis in mouse white adipose tissue, muscle, and liver: the role of eNOS, p38 MAPK, and AMPK pathways. Diabetes 2010, 59:2826-2836.
60. Perwitz N., et al. Cannabinoid type 1 receptor blockade induces transdifferentiation towards a brown fat phenotype in white adipocytes. Diabetes Obes. Metab. 2010, 12:158-166.
61. Mancini G., et al. Adipocye-specific CB1 conditional knock-out mice: new insights in the study of obesity and metabolic syndrome. 20th Annual Symposium on the Cannabinoids 2010, 17. International Cannabinoid Research Society.
62. Matias I., et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J. Clin. Endocrinol. Metab. 2006, 91:3171-3180.
63. D'Eon T.M., et al. The role of adipocyte insulin resistance in the pathogenesis of obesity-related elevations in endocannabinoids. Diabetes 2008, 57:1262-1268.
64. Buettner C., et al. Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanisms. Nat. Med. 2008, 14:667-675.
65. Jourdan T., et al. CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice. Diabetes 2010, 59:926-934.
66. Liu J., et al. Hepatic cannabinoid receptor-1 mediates diet-induced insulin resistance via inhibition of insulin signaling and clearance in mice. Gastroenterology 2012, 142:1218-1228.
67. Auguet T., et al. Endocannabinoid receptors gene expression in morbidly obese women with nonalcoholic fatty liver disease. Biomed. Res. Int. 2014, 2014:502542.
68. Osei-Hyiaman D., et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J. Clin. Invest. 2008, 118:3160-3169.
69. Tam J., et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J. Clin. Invest. 2010, 120:2953-2966.
70. Wu H.M., et al. Rimonabant, a cannabinoid receptor type 1 inverse agonist, inhibits hepatocyte lipogenesis by activating liver kinase B1 and AMP-activated protein kinase axis downstream of Galpha i/o inhibition. Mol. Pharmacol. 2011, 80:859-869.
71. Cinar R., et al. Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides. Hepatology 2014, 59:143-153.
72. Tam J., et al. Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab. 2012, 16:167-179.
73. Dallman M.F. Stress-induced obesity and the emotional nervous system. Trends Endocrinol. Metab. 2010, 21:159-165.
74. Bowles N.P., et al. A peripheral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome. Proc. Natl. Acad. Sci. U.S.A. 2015, 112:285-290.
75. Lipina C., et al. Regulation of MAP kinase-directed mitogenic and protein kinase B-mediated signaling by cannabinoid receptor type 1 in skeletal muscle cells. Diabetes 2010, 59:375-385.
76. Malenczyk K., et al. CB1 cannabinoid receptors couple to focal adhesion kinase to control insulin release. J. Biol. Chem. 2013, 288:32685-32699.
77. Jourdan T., et al. Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nat. Med. 2013, 19:1132-1140.
78. Kim W., et al. Cannabinoids induce pancreatic beta-cell death by directly inhibiting insulin receptor activation. Sci. Signal. 2012, 5:ra23.
79. Kim W., et al. Cannabinoids inhibit insulin receptor signaling in pancreatic beta-cells. Diabetes 2011, 60:1198-1209.
80. Engeli S., et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005, 54:2838-2843.
81. Bluher M., et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006, 55:3053-3060.
82. Cote M., et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int. J. Obes. 2007, 31:692-699.
83. Di Marzo V., et al. Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. Eur. J. Endocrinol. 2009, 161:715-722.
84. Gatta-Cherifi B., et al. Simultaneous postprandial deregulation of the orexigenic endocannabinoid anandamide and the anorexigenic peptide YY in obesity. Int. J. Obes. 2012, 36:880-885.
85. Abdulnour J., et al. Circulating endocannabinoids in insulin sensitive vs. insulin resistant obese postmenopausal women. A MONET group study. Obesity 2014, 22:211-216.
86. Matias I., et al. Role and regulation of acylethanolamides in energy balance: focus on adipocytes and beta-cells. Br. J. Pharmacol; 2007, 152:676-690.
87. Monteleone P., et al. Hedonic eating is associated with increased peripheral levels of ghrelin and the endocannabinoid 2-arachidonoyl-glycerol in healthy humans: a pilot study. J. Clin. Endocrinol. Metab. 2012, 97:E917-E924.
88. Monteleone A.M., et al. Deranged endocannabinoid responses to hedonic eating in underweight and recently weight-restored patients with anorexia nervosa. Am. J. Clin. Nutr. 2015, 101:262-269.
89. Bordicchia M., et al. Cannabinoid CB1 receptor expression in relation to visceral adipose depots, endocannabinoid levels, microvascular damage, and the presence of the Cnr1 A3813G variant in humans. Metabolism 2010, 59:734-741.
90. Baye T.M., et al. Genetic variation in cannabinoid receptor 1 (CNR1) is associated with derangements in lipid homeostasis, independent of body mass index. Pharmacogenomics 2008, 9:1647-1656.
91. Sipe J.C., et al. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int. J. Obes. (Lond.) 2005, 29:755-759.
92. Monteleone P., et al. The cDNA 385C to A missense polymorphism of the endocannabinoid degrading enzyme fatty acid amide hydrolase (FAAH) is associated with overweight/obesity but not with binge eating disorder in overweight/obese women. Psychoneuroendocrinology 2008, 33:546-550.
93. Sipe J.C., et al. Biomarkers of endocannabinoid system activation in severe obesity. PLoS ONE 2010, 5:e8792.
94. Hariri A.R., et al. Divergent effects of genetic variation in endocannabinoid signaling on human threat- and reward-related brain function. Biol. Psychiatry 2009, 66:9-16.
95. Tourino C., et al. FAAH deficiency promotes energy storage and enhances the motivation for food. Int. J. Obes. 2010, 34:557-568.
96. Vaitheesvaran B., et al. Peripheral effects of FAAH deficiency on fuel and energy homeostasis: role of dysregulated lysine acetylation. PLoS ONE 2012, 7:e33717.
97. Silvestri C., Di Marzo V. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders. Expert. Opin. Investig. Drugs 2012, 21:1309-1322.
98. Cluny N.L., et al. A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br. J. Pharmacol. 2010, 161:629-642.
99. Salamone J.D., et al. Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. Physiol. Behav. 2007, 91:383-388.
100. Sink K.S., et al. Oral bioavailability of the novel cannabinoid CB1 antagonist AM6527: effects on food-reinforced behavior and comparisons with AM4113. Pharmacol. Biochem. Behav. 2009, 91:303-306.
101. Cluny N.L., et al. The neutral cannabinoid CB(1) receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat. Pharmacol. Biochem. Behav. 2011, 97:537-543.
102. Heimann A.S., et al. Hemopressin is an inverse agonist of CB1 cannabinoid receptors. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:20588-20593.
103. Bauer M., et al. Identification and quantification of a new family of peptide endocannabinoids (Pepcans) showing negative allosteric modulation at CB1 receptors. J. Biol. Chem. 2012, 287:36944-36967.
104. Vallee M., et al. Pregnenolone can protect the brain from cannabis intoxication. Science 2014, 343:94-98.
105. Dodd G.T., et al. The peptide hemopressin acts through CB1 cannabinoid receptors to reduce food intake in rats and mice. J. Neurosci. 2010, 30:7369-7376.
106. Dodd G.T., et al. Central functional response to the novel peptide cannabinoid, hemopressin. Neuropharmacology 2013, 71:27-36.
107. Piazza, P.V. et al. INSERM and University of Bordeaux. Antagonists of CB1 receptor. Patent Publication WO/2012/160006; International Application PCT/EP2012/059310.
108. Kinsella J.E. Lipids, membrane receptors, and enzymes: effects of dietary fatty acids. JPEN J. Parenter. Enteral. Nutr. 1990, 14:200S-217S.
109. Di Marzo V. Endocannabinoids: synthesis and degradation. Rev. Physiol. Biochem. Pharmacol. 2008, 160:1-24.
110. Batetta B., et al. Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. J. Nutr. 2009, 139:1495-1501.
111. Berge K., et al. Chronic treatment with krill powder reduces plasma triglyceride and anandamide levels in mildly obese men. Lipids Health Dis. 2013, 12:78.
112. Pintus S., et al. Sheep cheese naturally enriched in alpha-linolenic, conjugated linoleic and vaccenic acids improves the lipid profile and reduces anandamide in the plasma of hypercholesterolaemic subjects. Br. J. Nutr. 2013, 109:1453-1462.
113. Kim J., et al. Fat to treat fat: emerging relationship between dietary PUFA, endocannabinoids, and obesity. Prostaglandins Other Lipid Mediat. 2013, 104-105:32-41.
114. Bisogno T., et al. A novel fluorophosphonate inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol with potential anti-obesity effects. Br. J. Pharmacol. 2013, 169:784-793.
115. Powell D.R., et al. Diacylglycerol lipase alpha knockout mice demonstrate metabolic and behavioral phenotypes similar to those of cannabinoid receptor 1 knockout mice. Front. Endocrinol. (Lausanne) 2015, 6:86.
116. Cota D., et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. 2003, 112:423-431.
117. Verty A.N., et al. Anti-obesity effects of the combined administration of CB1 receptor antagonist rimonabant and melanin-concentrating hormone antagonist SNAP-94847 in diet-induced obese mice. Int. J. Obes. 2013, 37:279-287.
118. White N.E., et al. Co-administration of SR141716 with peptide YY3-36 or oxyntomodulin has additive effects on food intake in mice. Diabetes Obes. Metab. 2008, 10:167-170.
119. Deveaux V., et al. Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS ONE 2009, 4:e5844.
120. Agudo J., et al. Deficiency of CB2 cannabinoid receptor in mice improves insulin sensitivity but increases food intake and obesity with age. Diabetologia 2010, 53:2629-2640.
121. Karaliota S., et al. Anandamide increases the differentiation of rat adipocytes and causes PPARgamma and CB1 receptor upregulation. Obesity 2009, 17:1830-1838.
122. Di Marzo V., De Petrocellis L. Endocannabinoids as regulators of transient receptor potential (TRP) channels: A further opportunity to develop new endocannabinoid-based therapeutic drugs. Curr. Med. Chem. 2010, 17:1430-1449.
123. DiPatrizio N.V., Piomelli D. Intestinal lipid-derived signals that sense dietary fat. J. Clin. Invest. 2015, 125:891-898.
124. Katona I., Freund T.F. Multiple functions of endocannabinoid signaling in the brain. Annu. Rev. Neurosci. 2012, 35:529-558.
125. Fu J., et al. A catalytically silent FAAH-1 variant drives anandamide transport in neurons. Nat. Neurosci. 2011, 15:64-69.
126. Leung K., et al. Role of FAAH-like anandamide transporter in anandamide inactivation. PLoS ONE 2013, 8:e79355.
127. Jones E.K., Kirkham T.C. Noladin ether, a putative endocannabinoid, enhances motivation to eat after acute systemic administration in rats. Br. J. Pharmacol. 2012, 166:1815-1821.
128. Pertwee R.G., et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol. Rev. 2010, 62:588-631.
129. Han J., et al. Acute cannabinoids impair working memory through astroglial CB1 receptor modulation of hippocampal LTD. Cell 2012, 148:1039-1050.
130. Bosier B., et al. Astroglial CB1 cannabinoid receptors regulate leptin signaling in mouse brain astrocytes. Mol. Metab. 2013, 2:393-404.
131. Horswill J.G., et al. PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. Br. J. Pharmacol. 2007, 152:805-814.